Last edition
News about "chronic urticaria"
Novartis' Remibrutinib Shows Positive Phase III Results in Chronic Inducible Urticaria
Pivotal RemIND trial meets primary endpoint across three major CIndU subtypes, positioning oral remibrutinib as a potential first targeted therapy for inducible chronic hives.
Chronic Urticaria | 19/02/2026 | By News Bureau | 125
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members